Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimer’s Disease
16 juil. 2023 03h00 HE
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimer’s Disease Small molecule varoglutamstat,...
Vivoryon Therapeutics N.V. Reports Outcome of 2023 Annual General Meeting
21 juin 2023 12h02 HE
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Reports Outcome of 2023 Annual General Meeting All proposed resolutions approvedElection of two new Non-Executive Board members Halle (Saale) / Munich, Germany, June...
Vivoryon Therapeutics N.V. Announces CEO Transition Plan
15 juin 2023 11h49 HE
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Announces CEO Transition Plan Dr. Ulrich Dauer not to extend current term running through 2024 AGMBoard to initiate succession planning Halle (Saale) / Munich,...
Vivoryon Therapeutics N.V. to Participate in Upcoming Conferences
01 juin 2023 01h00 HE
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. to Participate in Upcoming Conferences Halle (Saale) / Munich, Germany, June 1, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a...
Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 25 Million
26 mai 2023 01h39 HE
|
Vivoryon Therapeutics N.V.
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION...
Vivoryon Therapeutics Launches Capital Increase by Way of an Accelerated Bookbuild Offering
25 mai 2023 11h50 HE
|
Vivoryon Therapeutics N.V.
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION...
Vivoryon Therapeutics N.V. Reports Q1 2023 Financial Results and Highlights Operational Progress
16 mai 2023 01h00 HE
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Reports Q1 2023 Financial Results and Highlights Operational Progress Halle (Saale) / Munich, Germany, May 16, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY;...
Vivoryon Therapeutics N.V. to Hold its 2023 Annual General Meeting on June 21, 2023
09 mai 2023 01h02 HE
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. to Hold its 2023 Annual General Meeting on June 21, 2023 Halle (Saale) / Munich, Germany, May 9, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY;...
Vivoryon Therapeutics N.V. to Report Q1 2023 Financial Results and Operational Progress on May 16, 2023
09 mai 2023 01h00 HE
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. to Report Q1 2023 Financial Results and Operational Progress on May 16, 2023 Halle (Saale) / Munich, Germany, May 9, 2023 – Vivoryon Therapeutics N.V. (Euronext...
Vivoryon Therapeutics N.V. Announces Planned Changes to Board Composition at 2023 Annual General Meeting
01 mai 2023 04h00 HE
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Announces Planned Changes to Board Composition at 2023 Annual General Meeting Halle (Saale) / Munich, Germany, May 1, 2023 – Vivoryon Therapeutics N.V. (Euronext...